What it sells
Multi-omics plus AI for science research (per headline).
Business model breakdown
Buyer: who owns the budget?
UnverifiedPrincipal investigators and core facilities at universities, institutes and hospitals; biopharma QC/analytics teams.
Trigger: what makes them buy now?
Need omics data (metabolomics, proteomics, transcriptomics) and biologic characterization without owning mass-spec infrastructure.
Workflow: what inputs become what output?
Submit samples; service lab runs untargeted/targeted metabolomics, lipidomics, proteomics, PTMs, single-cell/spatial omics, sequencing and multi-omics, plus biologics characterization (structure, purity, glycosylation, affinity, cell activity); delivers data and analysis.
Economics: what it saves and how it charges
UnverifiedPer-sample, per-project service fees; also sells LIMS and automated sample-prep instruments (Qlab3).
Distribution: how it reaches customers
Direct sales through group sub-sites (Biotree Tech, Pharma, Overseas, Medical, Information) and online ordering/contact.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-10 | Series B | nearly CNY 100M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.